Literature DB >> 23187771

To transplant or not to transplant for adult acute myeloid leukemia: an ever-evolving decision.

Aaron T Gerds1, Frederick R Appelbaum.   

Abstract

In 2007, a group of experts charged by the American Society for Blood and Marrow Transplantation critically reviewed the available literature and summarized the indications for allogeneic hematopoietic cell transplantation versus chemotherapy in adults with acute myeloid leukemia. Much of the resulting position statement was based on studies conducted nearly 2 decades ago, and may not accurately represent current treatment. As a result of advances in both therapeutic regimens and supportive care, a number of recent studies have demonstrated clear and consistent improvements in the outcomes of patients receiving chemotherapy and allogeneic hematopoietic cell transplantation. In addition, prognostic accuracy has improved with the identification of mutations not detected by traditional cytogenetics. With these advancements in prognostic accuracy and treatment, it is now appropriate to revisit the indications for transplantation versus chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23187771      PMCID: PMC3895910     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  39 in total

1.  Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy.

Authors:  Hirotaka Takasaki; Masatsugu Tanaka; Takayoshi Tachibana; Ayumi Numata; Katsumichi Fujimaki; Rika Sakai; Shin Fujisawa; Naoto Tomita; Hiroyuki Fujita; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2012-03       Impact factor: 2.490

2.  Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.

Authors:  Felicitas Thol; Frederik Damm; Andrea Lüdeking; Claudia Winschel; Katharina Wagner; Michael Morgan; Haiyang Yun; Gudrun Göhring; Brigitte Schlegelberger; Dieter Hoelzer; Michael Lübbert; Lothar Kanz; Walter Fiedler; Hartmut Kirchner; Gerhard Heil; Jürgen Krauter; Arnold Ganser; Michael Heuser
Journal:  J Clin Oncol       Date:  2011-06-13       Impact factor: 44.544

3.  Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.

Authors:  Guido Marcucci; Klaus H Metzeler; Sebastian Schwind; Heiko Becker; Kati Maharry; Krzysztof Mrózek; Michael D Radmacher; Jessica Kohlschmidt; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

4.  Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

Authors:  Salut Brunet; Myriam Labopin; Jordi Esteve; Jan Cornelissen; Gerard Socié; Anna P Iori; Leo F Verdonck; Liisa Volin; Alois Gratwohl; Jorge Sierra; Mohamad Mohty; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

5.  Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study.

Authors:  Mats Remberger; Malin Ackefors; Sofia Berglund; Ola Blennow; Göran Dahllöf; Aldona Dlugosz; Karin Garming-Legert; Jens Gertow; Britt Gustafsson; Moustapha Hassan; Zuzana Hassan; Dan Hauzenberger; Hans Hägglund; Helen Karlsson; Lena Klingspor; Gunilla Kumlien; Katarina Le Blanc; Per Ljungman; Maciej Machaczka; Karl-Johan Malmberg; Hanns-Ulrich Marschall; Jonas Mattsson; Richard Olsson; Brigitta Omazic; Darius Sairafi; Marie Schaffer; Britt-Marie Svahn; Petter Svenberg; Lisa Swartling; Attila Szakos; Michael Uhlin; Mehmet Uzunel; Emma Watz; Annika Wernerson; Agneta Wikman; Ann-Charlotte Wikström; Jacek Winiarski; Olle Ringdén
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

6.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Georg N Franke; Ginna G Laport; Thomas R Chauncey; Edward Agura; Richard T Maziarz; Amelia Langston; Parameswaran Hari; Michael A Pulsipher; Wolfgang Bethge; Firoozeh Sahebi; Benedetto Bruno; Michael B Maris; Andrew Yeager; Finn Bo Petersen; Lars Vindeløv; Peter A McSweeney; Kai Hübel; Marco Mielcarek; George E Georges; Dietger Niederwieser; Karl G Blume; David G Maloney; Rainer Storb
Journal:  JAMA       Date:  2011-11-02       Impact factor: 56.272

7.  Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.

Authors:  Min Fang; Barry Storer; Elihu Estey; Megan Othus; Lisa Zhang; Brenda M Sandmaier; Frederick R Appelbaum
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

8.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Authors:  Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

9.  Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.

Authors:  Bruno Lioure; Marie C Béné; Arnaud Pigneux; Anne Huynh; Patrice Chevallier; Nathalie Fegueux; Didier Blaise; Brigitte Witz; Martine Delain; Jérôme Cornillon; Isabelle Luquet; Odile Blanchet; Pascale Cornillet-Lefebvre; Martin Carré; Mathilde Hunault; Fabrice Larosa; Thierry Lamy; Edouard Randriamalala; Mario Ojeda-Uribe; Christian Berthou; Luc Fornecker; Jean-Luc Harousseau; Didier Bouscary; Norbert Ifrah; Jean-Yves Cahn
Journal:  Blood       Date:  2012-02-09       Impact factor: 22.113

10.  Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

Authors:  S M Luger; O Ringdén; M-J Zhang; W S Pérez; M R Bishop; M Bornhauser; C N Bredeson; M S Cairo; E A Copelan; R P Gale; S A Giralt; Z Gulbas; V Gupta; G A Hale; H M Lazarus; V A Lewis; M C Lill; P L McCarthy; D J Weisdorf; M A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.